Carol g simon parking morristown hospital tn
Alabama
O’Neal Comprehensive Cancer Center at UAB
Spencer Cancer Center
Alaska
Central Peninsula Hospital
Arizona
Banner MD Anderson Cancer Center
HonorHealth Research and Innovation Institute
Ironwood Cancer & Research Centers
Mayo Clinic
University of Arizona Cancer Center
Arkansas
CARTI
CHI St. Vincent
St. Bernards Cancer Center
UAMS -- Winthrop P. Rockefeller Cancer Institute
California
Adventist Health
- Adventist Health Bakersfield
- Adventist Health Sonora
Ascending Medicine
Association of South Bay Surgeons
Cancer Resource Center of the Desert
Cedars-Sinai Medical Center
Chan Soon-Shiong Institute for Medicine
City of Hope
Color Health
Community Cancer Institute
Dignity Health
- French Hospital Medical Center
- Mercy San Juan Medical Center
- Sierra Nevada Memorial Hospital Community Cancer Center
Enloe Regional Cancer Center
Hoag Hospital Newport Beach
John Muir Health
Kaiser Permanente
- Ontario Medical Center
- Riverside Medical Center
- San Francisco Medical Center
- San Jose Medical Center
Los Robles Regional Medical Center
Medical Oncology Associates of San Diego
MemorialCare Todd Cancer Institute
Moores Cancer Center at UC San Diego Health
Naval Medical Center San Diego
Nurick Surgical Institute
Placentia-Linda Hospital
Pomona Valley Hospital Medical Center
Providence
- Holy Cross Medical Center
- Mission Hospital
Ridley-Tree Cancer Center
Saint Agnes Medical Center
Scripps MD Anderson Cancer Center
Sharp Memorial Hospital Outpatient Pavilion
Southern California Multi-Specialty Center
Sutter Health
- Memorial Medical Center
- Sutter Solano Medical Center
Torrance Memorial Medical Center
UC Davis Comprehensive Cancer Center
UCLA Health Santa Monica Cancer Care
UCSF Health
USC Norris Comprehensive Cancer Center
VyncaCare
Colorado
Rocky Mountain Cancer Centers
UCHealth
- Medical Center of the Rockies
- Memorial Hospital Central
Connecticut
Hartford Healthcare
- Hartford Healthcare Cancer
- 100 madison avenue morristown, nj 07960 phone number
- Gagnon center morristown hospital
- Morristown medical center phone number
100+ hospitals and health systems with great oncology programs | 2024
Becker's is proud to announce its 2024 list of hospitals and health systems recognized for excellence in oncology. These institutions have garnered national acclaim for advancing cancer care via their cutting-edge clinical trials and life-changing research.
Many of the listed cancer programs hold National Cancer Institute designations and are ranked among the nation’s top cancer care providers by U.S. News & World Report, Newsweek and other top rankings organizations. The list features cancer centers with globally renowned experts, innovative clinical trials and intensive safety protocols.
Note: This list is not exhaustive, nor is it an endorsement of included hospitals, health systems or associated healthcare providers. Organizations cannot pay for inclusion on this list. Organizations are presented in alphabetical order. We extend a special thank you to Rhoda Weiss for her contributions to this list.
We accepted nominations for this list. Contact Anna Falvey at afalvey@beckershealthcare.com with questions or comments.
AdventHealth – Central Florida Division (Orlando). The AdventHealth Cancer Institute team comprises over 300 providers and eight cancer centers, serving more than 21,000 cancer patients in Central Florida annually. In addition to providing whole-person care in infusion, radiation therapy, bone marrow transplants and more, the institute is one of the most active clinical research sites in Florida, conducting about 175 clinical trials annually with roughly 50 cancer-dedicated research employees. Recent service expansions include the head and neck cancer program expanding to three locations and adding two new infusion centers. In 2023, the division grew the expert team of clinicians with 14 new physicians and more than 20 advanced practice providers. In addition, AdventHealth Cancer Institute is first in the state to offer liver histotripsy as a treatment optio
Authors
Leigh Boehmer, PharmD, BCOP
Chief Medical Officer and
Deputy Executive Director for the
Association of Community Cancer Centers (ACCC)
Leigh Boehmer is the Chief Medical Officer and Deputy Executive Director for the Association of Community Cancer Centers (ACCC). In this role, he is responsible for assessing educational needs and designing interventions for multidisciplinary cancer care teams. He also serves as a liaison with patient advocacy organizations, policy experts, and governmental agencies to advance the objectives of ACCC. He has worked in both in- and outpatient medical oncology settings, spanning large academic to rural community oncology environments. His current areas of concentration include building capacity for community oncology research and mitigating cancer care disparities.
Learn More
Mandi Pratt-Chapman, MA, PhD, HON-OPN-CG
Associate Center Director,
Patient-Centered Initiatives & Health Equity,
GW Cancer Center
Washington, DC
Mandi Pratt-Chapman, PhD is Associate Center Director, Patient-Centered Initiatives and Health Equity for the GW Cancer Center. Her research has focused on workforce capacity to advance patient-centered care and health equity in oncology. She led the development of national, consensus-based core competencies; a no-cost training; and a certification process for patient navigators.
Learn More
Linda Burhansstipanov, MSPH, DrPH
Native American Cancer Research Corporation, Native American Cancer Initiatives, Inc, Denver, CO
Linda Burhansstipanov has worked in public health since 1971. She taught at universities for 18 years (CSULB and UCLA). She developed and implemented the Native American Cancer Research Program at the National Cancer Institute from 1989-1993. She is the founder of Native American Cancer Research Corporation (non-profit) and President of Native American Cancer Initiatives, Incorporated (for-profit). She currently is the principal investigator and subcontractor for
Abstract
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis. This planned analysis assessed the long-term efficacy and safety of ruxolitinib at a median follow-up of 149 weeks. At data cutoff, approximately 50% of patients originally randomized to ruxolitinib remained on treatment whereas all patients originally assigned to placebo had discontinued or crossed over to ruxolitinib. At week 144, mean spleen volume reduction was 34% with ruxolitinib. Previously observed improvements in quality-of-life measures were sustained with longer-term ruxolitinib therapy. Overall survival continued to favor ruxolitinib despite the majority of placebo patients crossing over to ruxolitinib [hazard ratio 0.69 (95% confidence interval: 0.46–1.03); P=0.067]. Exploratory analyses suggest that crossover may have contributed to an underestimation of the true survival difference between the treatment groups. Ruxolitinib continued to be generally well tolerated; there was no pattern of worsening grade ≥3 anemia or thrombocytopenia with longer-term ruxolitinib exposure. These longer-term data continue to support the efficacy and safety of ruxolitinib in patients with myelofibrosis. The study is registered at clinicaltrials.gov: NCT00952289.
Introduction
Myelofibrosis (MF) is a Philadelphia chromosome–negative myeloproliferative neoplasm that may occur as primary myelofibrosis (PMF) or develop from progression of polycythemia vera or essential thrombocythemia (post-polycythemia vera or post-essential thrombocythemia MF, respectively). The clinical hallmarks of MF are splenomegaly, cytopenias, and debilitating symptoms associated with a hypercatabolic state and systemic inflammation. Allogeneic stem cell transplantatio